The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients

INTRODUCTION: Synovial Sarcoma (SS) and Myxoid Round Cell Liposarcoma (MRCL) are devastating sarcoma subtypes with few treatment options and poor outcomes in the advanced setting. However, both these diseases may be ideal for novel immunotherapies targeting the cancer-testis antigen, NY-ESO-1. AREAS...

Descripción completa

Detalles Bibliográficos
Autor principal: Pollack, Seth M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521962/
https://www.ncbi.nlm.nih.gov/pubmed/29280411
http://dx.doi.org/10.1080/14760584.2018.1419068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521962/
https://www.ncbi.nlm.nih.gov/pubmed/29280411
http://dx.doi.org/10.1080/14760584.2018.1419068

Ejemplares similares